We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Scientific opinion from the UK Nutrition and Health Claims Committee (UKNHCC) for the substantiation of an Article 13(5) health claim: lutein, zeaxanthin and meso-zeaxanthin and improved visual performance.
JCVI statement setting out advice on the use of the 4CMenB vaccine for the prevention of gonorrhoea in those who are at increased risk of infection.
This report presents activity and payment statistics related to Northern Ireland Community Ophthalmic Services for quarter 4 2020/21.
This report presents activity and payment statistics related to Northern Ireland Community Ophthalmic Services for quarter 1 2021/22.
This report presents activity and payment statistics related to Northern Ireland Community Ophthalmic Services for quarter 2 2021/22.
This report presents activity and payment statistics related to Northern Ireland Community Ophthalmic Services for Quarter 1 2020/21.
This report presents activity and payment statistics related to Northern Ireland Community Ophthalmic Services for Quarter 2 2020/21.
Upper Tribunal Administrative Appeals Chamber decision by Judge Mitchell on 30 October 2023.
Employment Tribunal decision.
Following a review of the available toxicological data and a calculation of daily exposure to boron from a typical dosing regimen, we have concluded that the balance between the benefits and risks of chloramphenicol eye drops containing borax or boric...
Maintenance doses of brolucizumab (after the first 3 doses) should not be given at intervals of less than 8 weeks apart.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).